Home » Stocks » VERU

Veru Inc. (VERU)

Stock Price: $12.33 USD 0.14 (1.15%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $12.45 +0.12 (0.97%) Mar 5, 6:01 PM
Market Cap 942.71M
Revenue (ttm) 46.63M
Net Income (ttm) 1.56M
Shares Out 70.31M
EPS (ttm) 0.02
PE Ratio 536.09
Forward PE 217.39
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $12.33
Previous Close $12.19
Change ($) 0.14
Change (%) 1.15%
Day's Open 12.17
Day's Range 10.69 - 12.41
Day's Volume 1,871,715
52-Week Range 2.30 - 24.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast c...

Zacks Investment Research - 4 days ago

Veru (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 days ago

Veru Inc (NASDAQ: VERU) will start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Di...

Benzinga - 1 week ago

Veru Inc (NASDAQ: VERU) has submitted a 505(b)(2) New Drug Application with the FDA for TADFIN (tadalafil 5mg and finasteride 5mg) capsules, daily oral dosing combination formulation, for the ...

GlobeNewsWire - 1 week ago

--TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride ...

Benzinga - 2 weeks ago

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly ow...

Other stocks mentioned: NVTA, CYH, MTEM
Forbes - 2 weeks ago

The stock price of Veru Inc. , a biopharmaceuticals company focused on oncology medicines, has seen a monstrous 112% rise over the last ten trading days, while it's up 47% over the last five t...

Benzinga - 2 weeks ago

Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to pur...

GlobeNewsWire - 2 weeks ago

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast ca...

GlobeNewsWire - 2 weeks ago

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast ca...

Zacks Investment Research - 3 weeks ago

Female Health Company The (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead ...

Benzinga - 3 weeks ago

Shares of Veru (NASDAQ:VERU) moved higher by 17.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.02), whic...

GlobeNewsWire - 3 weeks ago

--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Pr...

The Motley Fool - 3 weeks ago

Analysts are excited about the potential of the biotech's experimental COVID-19 treatment.

CNBC - 3 weeks ago

Dr. Mitchell Steiner, chief executive of drugmaker Veru, said a Phase 2 trial of VERU-111 showed an 82% relative reduction in Covid-19 patient mortality versus placebo.

CNBC Television - 3 weeks ago

Veru CEO says cancer drug has potential to prevent Covid-19 deaths

Veru CEO Dr. Mitchell Steiner explained how VERU-111, a prostate cancer drug developed by the biotech company, could be used as an anti-inflammatory and antiviral treatment to help patients di...

The Motley Fool - 3 weeks ago

The company reported great results from a phase 2 study in treating hospitalized COVID-19 patients.

Benzinga - 3 weeks ago

Veru Inc (NASDAQ: VERU) rises sharply after announcing positive efficacy and safety results from a Phase 2 trial evaluating VERU-111 versus placebo in approximately 40 hospitalized patients at...

GlobeNewsWire - 3 weeks ago

– Potential for two-pronged action against COVID-19 as an antiviral and  anti-inflammatory agent supported by Phase 2 clinical study results –

Zacks Investment Research - 1 month ago

Female Health Company The (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast ca...

Forbes - 1 month ago

After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock, a biopharmaceuticals company focused on oncology medici...

GlobeNewsWire - 2 months ago

MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast ca...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

Market Watch - 2 months ago

Shares of Veru Inc. soared 51.4% toward a seven-year high on massive volume, after the biopharmaceutical company announced positive results from a Phase 2 study of its treatment of breast canc...

Benzinga - 2 months ago

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...

Other stocks mentioned: ANPC, ARPO, ARVN, SYBX
InvestorPlace - 2 months ago

Veru (VERU) stock is doing well on Monday after announcing positive news from a Phase 2 clinical trial of its breast cancer drug. The post VERU Stock News: 9 Things for Investors to Know About...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

-- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium –

GlobeNewsWire - 2 months ago

-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- -- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast...

Seeking Alpha - 2 months ago

Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Veru (NASDAQ:VERU) moved higher by 4.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 160.00% year over year to $0.03, which ...

GlobeNewsWire - 2 months ago

-- Transformation to P remium O ncology B iopharmaceutical C ompany with L ate - S tage Clinical Drug P ipeline F ocused on P rostate and B reast C ancer is C omplete -- -- Company Poised to I...

GlobeNewsWire - 2 months ago

—FY20 Full-Year Net Revenue s and Gross Profit Achieve Historical Highs  o f $4 3 M illion and $ 31 M illion , Respectively—

Benzinga - 2 months ago

Veru (NASDAQ:VERU) releases its next round of earnings this Wednesday, December 09. Here is Benzinga's essential guide to Veru's Q4 earnings report.

GlobeNewsWire - 3 months ago

MIAMI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate c...

GlobeNewsWire - 5 months ago

MIAMI, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostat...

CNBC Television - 5 months ago

Veru: The shift from the heavy cap-weighted names to a more broadening out of the market is underwy

Dan Veru of Palisade Capital Management discusses how a pickup in the broader market, outside of mega-cap tech and work-from home stocks, is an indication of an acceleration in global growth.

GlobeNewsWire - 5 months ago

—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program—

GlobeNewsWire - 5 months ago

MIAMI, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostat...

CNBC Television - 6 months ago

Veru: The Russell 200 has emerged as the reopening benchmark

Dan Veru, co-chairman and chief investment officer at Palisade Capital Management, talks about markets amid a rally in equities, pointing to the Russell 2000 as the best reflection of the econ...

Seeking Alpha - 6 months ago

Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of Veru (NASDAQ:VERU) rose 4% in pre-market trading after the company reported Q3 results.

GlobeNewsWire - 6 months ago

  --Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021-- --VERU-111 Phase 1b Clinical Trial...

InvestorPlace - 7 months ago

If you’re able to overlook the shortcomings of these seven sin stocks, your long-term gains will be enough to soothe your conscience.

Other stocks mentioned: APHA, DKNG, LMT, MGM, MO, SAM
GlobeNewsWire - 7 months ago

--VERU-111 significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome in COVID-19 in a toxic shock model--  --VERU-111’s ability to disrupt microtubules has potent...

GlobeNewsWire - 7 months ago

MIAMI, July 30, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate...

GlobeNewsWire - 7 months ago

MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate...

CNBC Television - 7 months ago

Veru: There's much more opportunity, better valuations within the Russell 2000 than S&P 500

Dan Veru, co-chairman and CEO at Palisade Capital Management, talks small-cap stocks and investor strategy amid the COVID-19 pandemic.

GlobeNewsWire - 7 months ago

--Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021-- --Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021--

About VERU

Veru, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clin... [Read more...]

Industry
Biotechnology
IPO Date
Jul 19, 1990
CEO
Overton Parrish
Employees
339
Stock Exchange
NASDAQ
Ticker Symbol
VERU
Full Company Profile

Financial Performance

In 2020, Veru Inc.'s revenue was $42.59 million, an increase of 33.92% compared to the previous year's $31.80 million. Losses were -$18.97 million, 57.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Veru Inc. stock is "Strong Buy." The 12-month stock price forecast is 24.75, which is an increase of 100.73% from the latest price.

Price Target
$24.75
(100.73% upside)
Analyst Consensus: Strong Buy